Novartis has the option to sell its stake in its GlaxoSmithKline consumer health JV to its partner. But it doesn’t sound like that’s what the Swiss drugmaker’s plotting.
As outgoing CEO Joe Jimenez and successor Vas Narasimhan told Bernstein analyst Tim Anderson, the company believes there are a couple years to go before the venture reaches its full potential.
“We want to see the synergies from the combination continue to mature, allowing the stake to increase in value,” they said in quotes paraphrased by Anderson, adding that, “once that happens, we can evaluate what is the right thing to do with that capital.”
As Anderson wrote in a note to clients, that answer “clearly reads that Novartis will not be ‘putting’ its stake to GSK anytime soon,” despite earlier rumors that the Swiss drugmaker could use the money to fund big-time M&A.
Novartis and Glaxo first formed the industry-leading JV in early 2015 with the close of their three-part, multibillion-dollar asset swap. GSK agreed to hold the controlling stake, taking the burden off Novartis, which had been struggling in the consumer health department thanks to quality-control issues and product recalls.
And since then, Glaxo has echoed Jimenez and Narasimhan’s message, ignoring calls for a spinoff and insisting that the unit needed time to come into its own.
Meanwhile, the Jimenez and Narasimhan’s comments should “ease investor concern” about Glaxo scrapping its dividend, Anderson figures—unless, of course, it decides to use the money to go after Pfizer’s consumer business, an asset CEO and former consumer head Emma Walmsley has said the company is looking at.
By Carly Helfand
Source: Fierce Pharma
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.